首页> 外文OA文献 >Latest Clinical Approaches in the Ocular Management of Cystinosis: A Review of Current Practice and Opinion from the Ophthalmology Cystinosis Forum
【2h】

Latest Clinical Approaches in the Ocular Management of Cystinosis: A Review of Current Practice and Opinion from the Ophthalmology Cystinosis Forum

机译:半胱氨酸症眼部管理的最新临床方法:对眼科性胱素病论的当前实践与意见综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Cystinosis, a rare autosomal recessive disease caused by intracellular cystine accumulation, occurs in an estimated 1/100,000–200,000 live births. Ocular non-nephropathic cystinosis is typically diagnosed during adulthood, when patients present with corneal crystal deposition and no systemic involvement. Due to the rarity of the condition, diagnosis is often delayed and can have a significant impact on the overall prognosis of the disease. Early diagnosis is therefore imperative to ensure successful treatment and improve quality of life, as most of its clinical manifestations can be prevented or delayed. Early detection strategies and practical approaches for the ocular management of cystinosis were discussed during the Ophthalmology Cystinosis Forum, a 1-day meeting held in Berlin, Germany during June 2017. Recommendations for early detection comprise ophthalmic assessment, including self- and clinician-assessed recording of photophobia, and visual acuity, slit-lamp examination and tonometry ophthalmic examinations. In vivo confocal microscopy and anterior segment optical coherence tomography were highlighted as valuable techniques in evaluating cystine crystals in the cornea, in vivo and non-invasively. The mainstay of ocular cystinosis treatment is the cystine-depleting aminothiol cysteamine. Indeed, early treatment with and strict adherence to cysteamine therapy has a considerable impact on the long-term prognosis of ocular cystinosis. In rare diseases such as ocular cystinosis, standardised guidelines and recommendations for detection, patient care and follow-up assessments are essential. Such guidelines provide a support tool for healthcare professionals caring for ocular cystinosis patients. Multidisciplinary teams (MDTs) are essential for delivering gold standard care and improving quality of life for patients and their families. This review paper highlights current early detection policies, clinical treatment strategies and practical approaches for the ocular management of cystinosis, including implementing a cystinosis MDT. Additionally, discussions of the Ophthalmology Cystinosis Forum held in 2017 are summarised. Funding Orphan Europe. Plain Language Summary Plain language summary available for this article.
机译:摘要半立体,一种由细胞内胱氨酸积累引起的稀有常染色体隐性疾病,估计1 / 100,000-200,000活产出生。当患者存在角膜晶体沉积和全身累积时,目前在成年期间通常在成年期间被诊断为眼部非肾病囊肿。由于病症的罕见,诊断往往延迟,并且可能对疾病的整体预后产生重大影响。因此,早期诊断必须确保成功治疗和提高生活质量,因为其大部分临床表现都可以防止或延迟。在2017年6月德国柏林举行的一天会议期间讨论了早期检测策略和实用方法,术语半胱易生术中的半胱易生素病毒治疗术语。德国柏林举行的一天会议。早期检测的建议包括眼科评估,包括自我和临床医生评估的录音镜片,视力,狭缝灯检查和润泽眼镜检查。在体内共聚焦显微镜和前段光学相干断层扫描中被突出显示为在角膜中的胱氨酸晶体,体内和非侵入性地评估胱氨酸晶体中的有价值的技术。眼性胱素病治疗的主要支柱是胱氨酸耗尽的氨基硫醇半胱胺。实际上,早期治疗和严格遵守半胱胺治疗对眼睑症的长期预后具有相当大的影响。在稀有疾病如眼睑症,标准化指导方针和检测的建议,患者护理和后续评估是必不可少的。此类指南为医疗专业人士提供了关怀眼睑症患者的支持工具。多学科团队(MDTS)对于提供黄金标准护理并提高患者及其家庭的生活质量至关重要。本综述介绍目前的早期检测政策,临床治疗策略和胱氨酸眼肌肉治疗的实用方法,包括实施半胱氨酸MDT。此外,总结了2017年举行的眼科半胱氨酸论坛的讨论。资金孤儿欧洲。纯语言摘要纯语言摘要可用于本文。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号